The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
- MHLW Study Group Compiles Guideline for Collecting COVID-19 Convalescent Plasma
March 2, 2021
- 172 Vials of Pfizer Vaccine Unusable due to Freezer Breakdown
March 2, 2021
- MHLW Asks Municipalities to Secure Adrenaline Preparations for Anaphylaxis
March 1, 2021
- PAFSC Minutes for Pfizer Vaccine Disclosed
March 1, 2021
- Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
- MHLW Orders Label Revisions for NSAIDs, Salbutamol, Kymriah
March 1, 2021
- Japan Research Group to Wrap Up Report on Clinical Trials for Cannabis-Derived Drugs by March-End
February 26, 2021
- Key Panel Gives Thumbs-Up to Teijin’s Osteoporosis Med, JCR’s Hunter Syndrome Drug and More
February 26, 2021
- Japan Might Ease Temperature Requirements for Pfizer Vaccine
February 26, 2021
- MHLW Panel Shelves Decision on Bayer’s Heart Failure Med Vericiguat
February 26, 2021
- CSL Plans Export of 2 Surplus Human Immunoglobulin Products
February 26, 2021
- 17,888 Doses of COVID-19 Vaccine Given in Japan as of Feb. 24
February 25, 2021
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- MHLW Approves Add’l Use for Thaled, Bavencio and More
February 25, 2021
- 10,000 COVID-19 Patients Received Avigan in Observational Studies: Govt
February 25, 2021
- MHLW Formally Adopts GS1 Codes for Electronic Package Inserts; Rule to Take Effect August 1
February 25, 2021
- Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
- MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
- 4 APIs/9 Products Excluded from Kobayashi Kako Biz Suspension for Medical Needs
February 24, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…